Tag
This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone thera
Estradiol-based hormone therapy’s impact on memory varies by administration route—with transdermal delivery linked to better episodic memory and oral delivery to improved prospective memory. Earlier menopause onset correlates with poo
The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reprod
This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.
Large-scale UK data reveal a transient increase but sustained long-term reduction in fracture risk after discontinuing menopausal HRT, challenging prior assumptions and guiding future clinical decisions.
Leading experts call on the FDA to update boxed warnings on menopausal hormone therapies, arguing current labels are outdated and deter women from effective, safe treatments.
A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.
The FDA delays its review of Bayer’s elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.
Explore the science behind early menopause, its causes, common misconceptions, and evidence-based health recommendations for women.
